NCT03565367View on ClinicalTrials.gov

Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With Central Nervous System Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 6, 2018

Primary Completion Date

June 20, 2019

Study Completion Date

June 20, 2019

Conditions
Malignant Central Nervous System NeoplasmMetastatic Malignant Neoplasm in the Central Nervous System
Interventions
OTHER

Gadolinium

gadolinium enhanced MRI

DRUG

Hyperpolarized Carbon C 13 Pyruvate

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Magnetic Resonance Spectroscopic Imaging

Undergo MRSI

Trial Locations (1)

94304

Stanford University School of Medicine, Palo Alto

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

Daniel M. Spielman

OTHER

NCT03565367 - Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With Central Nervous System Tumors | Biotech Hunter | Biotech Hunter